ACOR News and Press, Acorda Therapeutics Inc. From 10/05/23

Acorda Therapeutics, Inc. (NASDAQ: ACOR) is one of today's top gainers. The company's shares are currently up 9.09% on the day to $12.22. Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company m...

2023-08-08 22:24:06 ET Acorda Therapeutics, Inc. (ACOR) Q2 2023 Earnings Conference Call August 08, 2023 04:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO ...

2023-08-08 16:41:26 ET Acorda Therapeutics press release ( NASDAQ: ACOR ): Q2 GAAP EPS of -$7.55. Revenue of $29.68M (-4.4% Y/Y). Outlook: For the full year 2023, the Company revised INBRIJA U.S. net revenue guidance to be $34-$38 million, from $38-$42 mi...

INBRIJA ® (levodopa inhalation powder) Q2 2023 U.S. net revenue of $8.3 million, a 12% increase from Q2 2022; ex-U.S. net revenue of $0.8 million New INBRIJA prescription request forms increased 42% in 1H 2023 over 2022 AMPYRA ® (dalfampridine) Extended Release Tablets, ...

2023-08-07 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign. The campaign, “For the Fighters, ” is based on direct feedback from people with Parkinson’s (PwPs). It honors the fighting ...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its second quarter 2023 update and financial results on Tuesday, August 8 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.c...

2023-07-19 13:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Jeff Randall Rotates off the Board Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Tom Burns, Chief Financial Officer at XOMA Corporation, has been elected to its Board of Directors by the stockholders at the Company’s Annual Meeting. Jeff Randall, who had served on...

2023-06-26 10:39:50 ET Biopharmaceutical company Acorda Therapeutics ( NASDAQ: ACOR ) said on Monday that it has received Nasdaq notice on having regained compliance with the stock exchange's minimum bid price requirement. The company had carried out a 1-for-20 r...